Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: a multicenter real-world study.

ABSTRACT:

Background

In previous clinical trials, pyrotinib has shown good antitumor activity and manageable toxicity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, real-world data on pyrotinib remain limited. In this study, we reported the latest real-world data on the efficacy and safety of pyrotinib in HER2-positive MBC.

Methods

This multicenter retrospective study included 337 HER2-positive MBC patients treated with pyrotinib between October 2016 and October 2024. We reported the analysis of the efficacy and safety of pyrotinib in HER2-positive MBC. The primary endpoints were progression-free survival (PFS) and overall survival (OS).

Results

As of April 1, 2025, the median follow-up duration was 42.6 months (range, 2.0-9

SUBMITTER: Li S 

PROVIDER: S-EPMC12574323 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature